Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Labarrere, Carlos A ^a,b   Woods, John R ^c   Hardin, James W ^d   Jaeger, Beate R ^e   Zembala, Marian ^f   Deng, Mario C ^g   Kassab, Ghassan S ^b  

^a CBL Partners for Life   (United States)

^b CALIFORNIA MEDICAL INNOVATIONS INSTITUTE   (United States)

^c METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Dr Stein und Kollegen   (Germany)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOSIS; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; GRAFT REJECTION; METABOLISM; STATISTICAL MODEL;

CHICKEN ANEMIA VIRUS;

ADULT; ATHEROSCLEROSIS; BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84916888680     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113260     Document Type: Article

References (55)

1. Dhaliwal A, Thohan V (2006) Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation. Curr Atheroscler Rep 8: 119-130.
2. Mehra MR (2006) Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 6: 1248-1256.
3. Labarrere C, Lee J, Nelson D, Al-Hassani M, Miller S, et al. (2002) Elevated levels of C-reactive protein are associated with arterial endothelial activation and development of transplant coronary artery disease. Lancet 360: 1462-1467.
4. Labarrere CA, Nelson DR, Faulk WP (1997) Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 278: 1169-1175.
5. Labarrere CA, Nelson DR, Miller SJ, Nieto JM, Conner JA, et al. (2000) Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. Circulation 102: 1549-1555.
6. Labarrere CA, Nelson DR, Cox CJ, Pitts D, Kirlin P, et al. (2000) Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 284: 457-464.
7. Labarrere CA, Nelson DR, Faulk WP (1998) Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 105: 207-213.
8. Labarrere CA, Torry RJ, Nelson DR, Miller SJ, Pitts DE, et al. (2001) Vascular antithrombin and clinical outcome in heart transplant patients. Am J Cardiol 87: 425-431.
9. Labarrere CA, Pitts D, Nelson DR, Faulk WP (1995) Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 333: 1111-1116.
10. Labarrere CA, Woods JR, Hardin JW, Campana GL, Ortiz MA, et al. (2012) Value of the first posttransplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients. PloS ONE 7: e36100.
11. Labarrere CA, Woods JR, Hardin JW, Campana G, Ortiz MA, et al. (2011) Early Prediction of Cardiac Allograft Vasculopathy and Heart Transplant Failure. Am J Transplant 11: 528-535.
12. Pethig K, Heublein B, Kutschka I, Haverich A (2000) Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102: III233-236.
13. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172; discussion 207-112.
14. Efron B (1979) Bootstrap methods: Another look at the jackknife. Annals of Statistics 7: 1-26.
15. Schisterman EF, Perkins NJ, Liu A, Bondell H (2005) Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 16: 73-81.
16. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
17. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. The New England Journal of Medicine 355: 2631-2639.
18. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American journal of epidemiology 159: 882-890.
19. Shah PK (2000) Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. Circulation 101: 1758-1759.
20. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, et al. (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242.
21. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1998) Plasma concentration of Creactive protein and risk of developing peripheral vascular disease. Circulation 97: 425-428.
23. Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97: 2007-2011.
24. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731-733.
25. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, et al. (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99: 855-860.
26. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349: 462-466.
27. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, et al. (1994) The prognostic value of Creactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424.
28. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, et al. (1998) Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 82: 715-719.
29. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332: 635-641.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844.
31. Labarrere CA, Zaloga GP (2004) C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 117: 499-507.
32. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168.
33. Singh U, Devaraj S, Jialal I (2005) C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25: 2216-2221.
34. Eisenberg MS, Chen HJ, Warshofsky MK, Sciacca RR, Wasserman HS, et al. (2000) Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102: 2100-2104.
35. Kerr R, Stirling D, Ludlam CA (2001) Interleukin 6 and haemostasis. British journal of haematology 115: 3-12.
36. Christenson RH, deFilippi CP, Kreutzer D (2005) Biomarkers of ischemia in patients with known coronary artery disease: do interleukin-6 and tissue factor measurements during dobutamine stress echocardiography give additional insight? Circulation 112: 3215-3217.
37. Ikonomidis I, Athanassopoulos G, Lekakis J, Venetsanou K, Marinou M, et al. (2005) Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study. Circulation 112: 3272-3279.
38. Wung BS, Hsu MC, Wu CC, Hsieh CW (2005) Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sciences 78: 389-397.
39. Wung BS, Ni CW, Wang DL (2005) ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. Journal of biomedical science 12: 91-101.
40. Hognestad A, Endresen K, Wergeland R, Stokke O, Geiran O, et al. (2003) Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. [comment]. J Am Coll Cardiol 42: 477-482.
41. Gullestad L, Simonsen S, Ueland T, Holm T, Aass H, et al. (1999) Possible role of proinflammatory cytokines in heart allograft coronary artery disease. American Journal of Cardiology 84: 999-1003.
42. Lowe GD, Pepys MB (2006) C-reactive protein and cardiovascular disease: weighing the evidence. Current atherosclerosis reports 8: 421-428.
43. Ventura HO, Mehra MR (2003) C-Reactive protein and cardiac allograft vasculopathy. is inflammation the critical link? J Am Coll Cardiol 42: 483-485.
44. Schmauss D, Weis M (2008) Cardiac allograft vasculopathy: recent developments. Circulation 117: 2131-2141.
45. Harrell F Jr (2001) Regression modeling strategies: with appllications to linear models, logistic regression, and survival analysis. New York: Springer.
46. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, et al. (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440: 1217-1221.
47. Labarrere CA, Pitts D, Halbrook H, Faulk WP (1994) Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients. An immunocytochemical study. Circulation 89: 1599-1608.
48. Labarrere CA, Pitts D, Nelson DR, Faulk WP (1995) Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc 27: 1939-1940.
49. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, et al. (2006) Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189: 83-90.
50. Ajeganova S, de Faire U, Jogestrand T, Frostegard J, Hafstrom I (2012) Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis-an inception cohort study. J Rheumatol 39: 1146-1154.
51. Anania C, Gustafsson T, Hua X, Su J, Vikstrom M, et al. (2010) Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 12: R214.
52. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, et al. (2007) Phosphorylcholinetargeting immunization reduces atherosclerosis. J Am Coll Cardiol 50: 540-546.
53. de Faire U, Frostegard J (2009) Natural antibodies against phosphorylcholine in cardiovascular disease. Ann N Y Acad Sci 1173: 292-300.
54. de Faire U, Su J, Hua X, Frostegard A, Halldin M, et al. (2010) Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 34: 73-79.
55. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, et al. (2009) Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120: 417-426.